Impact of carvedilol on the metabolism, inflammatory response and cardiac function of patients with diabetic cardiomyopathy

ObjectiveTo discuss the impacts of carvedilol on metabolism, inflammatory response and cardiac function of patients with diabetic cardiomyopathy(DCM).

MethodsOne hundred and eighty DCM patients were divided into the control group(n=88)and observation group(n=92)according to random number method in our hospital.The control group were treated with conventional method, and the observation group were additionally treated with carvedilol(3.125~6.25 mg/d)based on conventional method.After 12 weeks of treatment, the biochemical indexesincluding total cholesterol(TC), triglyceride(TG)and fasting blood-glucose(FBG), inflammation markersincluding high-sensitivity C-reactive protein(hs-CRP)and tumour necrosis factor-α(TNF-α), heart function parametersincluding left ventricular end diastolic diamete(LVEDd), left ventricular end-systolic diameter(LVEDs), left ventricular ejection fraction(LVEF), N-terminal pro-brain natriuretic peptid(NT-pro-BNP)and 6mmin walking distance and adverse reaction were compared between two groups.

ResultsAfter treatment, the levels of hs-CRP and TNF-αin two groups significantly decreased(P < 0.01), and the levels of hs-CRP and TNF-α in observation group were significantly lower than those in control group(P < 0.01).After treatment, the levels of LVEDd, LVEDs and NT-pro BNP significantly decreased(P < 0.01), and the LVEF level and 6min walking distance significantly increased in two groups(P < 0.01).After treatment, the levels of LVEDd, LVEDs and NT-pro BNP in observation group were significantly lower than those in control group(P < 0.01), and the LVEF level and 6min walking distance in observation group were significantly higher than those in control group(P < 0.01).No severe adverse reaction occurred in two groups.The dry cough in 2 cases and headache in 3 cases in control group, and dizziness and headache in 5 cases and dizziness and nausea in 1 case in observation group were found, and the difference of the incidence of adverse reactions between two groups was not statistically significant(P>0.05).

ConclusionsThe carvedilol can obviously improve the inflammatory state and cardiac function of DCM patients, and there is not significant effect on blood lipid and blood glucose.